Clin Neuro Mnd Davidson06.

1,163 views

Published on

Medical college lectures: neurology 5th year.

  • Be the first to comment

Clin Neuro Mnd Davidson06.

  1. 1. Motor neuron disease MND:ALS Dr. Mohammad Shaikhani.
  2. 2. Lou Gehrig’s Disease <ul><li>A well-known baseball player. </li></ul><ul><li>He was diagnosed with ALS. </li></ul><ul><li>Within a year, he could not walk or talk. </li></ul><ul><li>He died in 1941. </li></ul>
  3. 3. MND (ALS): <ul><li>A progressive disorder of unknown cause. </li></ul><ul><li>There is degeneration of motor neurons in the spinal cord,cranial nerve nuclei& pyramidal neurons in the motor cortex. </li></ul><ul><li>5% of cases are familial, AD,the genetic defect on ch 21, the enzyme involved superoxide dismutase (SOD1). </li></ul><ul><li>For the remaining 95%, ? viral infection, trauma, exposure to toxins , electric shock. </li></ul><ul><li>The prevalence 5/100 000. </li></ul>
  4. 4. MND (ALS):
  5. 5. Clinical features: <ul><li>A combination of lower &upper motor neuron signs without sensory involvement. </li></ul><ul><li>The presence of brisk reflexes in wasted fasciculating limb muscles is typical. </li></ul><ul><li>In many patients the clinical features are highly suggestive but alternative diagnoses need to be carefully excluded specially potentially treatable disorders as; </li></ul><ul><li>Diabetic amyotrophy. </li></ul><ul><li>Spinal disorders . </li></ul><ul><li>Multifocal motor neuronopathy. </li></ul><ul><li>EMG helps to confirm presence of fasciculation /denervation, specially helpful when pyramidal features predominate. </li></ul><ul><li>Sensory/motor conduction studies are normal but there may be some reduction in amplitude of action potentials due axon loss. </li></ul><ul><li>Spinal imaging / brain scanning may be necessary to exclude focal spinal or cerebral disease. </li></ul><ul><li>CSF exam is usually normal, though a slight elevation in protein may be found. </li></ul>
  6. 6. Clinical features: <ul><li>Usually after 50 years </li></ul><ul><li>Very uncommon before 30 years </li></ul><ul><li>Affects males > females </li></ul>Onset
  7. 7. Clinical features: Symptoms <ul><li>Limb muscle weakness, cramps, occasionally fasciculation </li></ul><ul><li>Disturbance of speech/swallowing (dysarthria/dysphagia) </li></ul>
  8. 8. Clinical features: Signs Signs Signs <ul><li>Wasting and fasciculation of muscles </li></ul><ul><li>Weakness of muscles of limbs, tongue, face & palate </li></ul><ul><li>Pyramidal signs: spasticity, inc tendon reflexes, extensor plantar. </li></ul><ul><li>External ocular muscles intact. </li></ul><ul><li>Sphincters remain intact. </li></ul><ul><li>No objective sensory deficit. </li></ul><ul><li>No intellectual impairment in most cases. </li></ul>
  9. 9. Clinical features: course Signs Signs Symptoms often begin focally in one part & spread gradually but eventually become widespread
  10. 10. Clinical features: involvement patterns Signs Signs 1.Progressive muscular atrophy Predominantly spinal motor neurons affected Weakness / wasting of distal limb muscles at first Fasciculation in muscles Tendon reflexes may be absent
  11. 11. Clinical features: involvement patterns Signs Signs 2.Progressive bulbar palsy <ul><li>Early involvement of tongue, palate and pharyngeal muscles </li></ul><ul><li>Dysarthria/dysphagia </li></ul><ul><li>Wasting / fasciculation of tongue </li></ul><ul><li>+/- pyramidal signs. </li></ul>
  12. 12. Clinical features: involvement patterns Signs Signs 3.Amyotrophic lateral sclerosis <ul><li>Combination of distal & proximal muscle-wasting & weakness, fasciculation </li></ul><ul><li>Spasticity, exaggerated reflexes, extensor plantars </li></ul><ul><li>Bulbar & pseudobulbar palsy follow eventually </li></ul><ul><li>Pyramidal tract features may predominate </li></ul>
  13. 13. DD: Signs Signs
  14. 14. Management: <ul><li>The glutamate antagonist, riluzole, shown to have a small effect in prolonging life expectancy by about 2 month. </li></ul><ul><li>It is not clear at which stage of the illness this prolongation occurs, so may not be particularly helpful. </li></ul><ul><li>Other agents such as nerve growth factor show promise. </li></ul><ul><li>Psychological / physical support, with help from occupational / speech therapists / physiotherapists, are essential to maintain the patient's quality of life. </li></ul><ul><li>Mechanical aids such as splints, walking aids, wheelchairs / communication devices all help to reduce handicap. </li></ul><ul><li>Feeding by percutaneous gastrostomy may be necessary if bulbar palsy is marked. </li></ul><ul><li>Sometimes non-invasive ventilatory support may help distress from weak respiratory muscles although maintenance ventilation is usually not requested. </li></ul><ul><li>Relief of distress in the terminal stages usually requires the use of opiates & sedative drugs. </li></ul>
  15. 15. Management: <ul><li>The only drug currently available is riluzole (2-amino-6-[trifluoromethoxy]benzothiazole). </li></ul><ul><li>Riluzole blocks glutamic acid release, may slow disease progression by disrupting glutamate-mediated neurotoxicity. </li></ul><ul><li>Administered at 50 mg twice a day, </li></ul><ul><li>Riluzole is generally well-tolerated,but may cause nausea , general asthenia& methaemoglobinura in overdose. </li></ul>
  16. 16. Management:Future <ul><li>1.long-term ceftriaxone slowed the course of disease in a mouse model, if given in high doses at the onset of the disease, preserved grip strength, slowed weight loss, & increased the overall duration of survival from 122 - 132 days &the mechanism is by modulating glutamate transport. </li></ul><ul><li>2.Gene therapy </li></ul><ul><li>3. RNA silencing </li></ul>
  17. 19. Prognosis: <ul><li>It is progressive; the mean time from diagnosis to death is 1 year, with most patients dying within 3-5 years of the onset of symptoms. </li></ul><ul><li>Younger patients & those with early bulbar symptoms tend to show a more rapid course. </li></ul><ul><li>Death is usually from respiratory infection / failure& the complications of immobility. </li></ul>
  18. 22. TYPES OF SPINAL MUSCULAR ATROPHY Good Facial / bulbar weakness, proximal limb weakness, gynaecomastia X-linked Adult life, males only Bulbospinal Good, seldom disabling Distal weakness and wasting of hands and feet Autosomal dominant Early adult life Distal forms Slowly progressive disability Proximal weakness and wasting, EMG shows denervation Autosomal recessive Childhood, adolescence Kugelberg-Welander Poor Severe muscle-wasting/weakness Autosomal recessive Infancy Werdnig-Hoffmann Prognosis Features Inheritance Onset Type

×